Conference
M34 Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the tomorrow and inpulsis trials
Abstract
Nintedanib is a tyrosine kinase inhibitor, a drug class that may be associated with increased risk of arterial thromboembolic events. The efficacy and safety of 52 weeks’ treatment with nintedanib versus placebo in patients with IPF were assessed in the TOMORROW and INPULSIS trials. Patients with myocardial infarction in the previous 6 months, unstable angina in the previous month, or stroke in the previous year were excluded. We assessed the …
Authors
Noth I; Wijsenbeek M; Kolb M; Bonella F; Moros L; Wachtlin D; Corte T
Volume
72
Publisher
BMJ
Publication Date
12 2017
DOI
10.1136/thoraxjnl-2017-210983.456
Name of conference
Idiopathic pulmonary fibrosis treatment update
Conference proceedings
Thorax
Issue
Suppl 3
ISSN
0040-6376